Therapeutic Response Statement (Sensitivity)

This therapeutic response statement Supports the relationship that CD19 + status confers therapeutic sensitivity to Blinatumomab in patients with Acute Lymphoblastic Leukemia.

Health Canada approved blinatumomab for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

This statement is based on a regulatory approval from the Health Canada:

BLINCYTO (blinatumomab for injection) is indicated for the treatment of adult patients with relapsed or refractory B-cell precursor ALL.

Citation

Amgen Canada Inc. Blincyto (blinatumomab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00083697.PDF. Revised February 2026. Accessed April 2026.

Contributions

Date	Contributor	Description
2024-10-30	Van Allen lab	Initial access of FDA approvals